179 completed, 22 unknown, 19 terminated, 5 withdrawn. 62 Phase 4, 45 Phase 3, 42 Phase 1, 42 Phase 2, 28 Not applicable.
Follow Raltegravir Potassium: new trials by email Literature Review of Raltegravir Potassium trials Research Report on Raltegravir Potassium
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Research on the Psychological Status of Patients With HIV-1 Infection All kinds of INSTI medications, All kinds of conventional medications - HIV-1-infection, Anxiety Depression | Not yet recruiting | Shanxi Bethune Hospital | 500 | 2025-08-01 | 2025-07-23 | |
| Pregnancy and Neonatal Outcomes Following Antenatal Exposure to Raltegravir: a Pooled Analysis From the European Pregnancy and Paediatric Infections Cohort Collaboration (EPPICC) Raltegravir - HIV Infections | Unknown | Fondazione Penta UK | 1200 | 2023-02-20 | 2023-03-02 | |
| Combination Antiretroviral Therapy (cART) for PBC Emtricitabine (FTC)/Tenofovir Disoproxil (TDF), Raltegravir, Placebo Oral Capsule [CEBOCAP] - Primary Biliary Cholangitis | Phase 2 | Completed | University of Alberta | 37 | 2021-03-01 | 2024-02-16 |
| The Influence of Concurrent Oral Calcium Carbonate Supplementation on Steady State Pharmacokinetics of Oral Raltegravir. Raltegravir standard dosage of 1200 mg (two 600 mg tablets) orally once daily., Calcium carbonate antacid tablet - Calcium Supplementation in HIV Patients Using Raltegravir | Phase 4 | Unknown | Ottawa Hospital Research Institute | 12 | 2020-12-09 | 2023-12-12 |
| HIV-1 Infected Patients, Phase II Trial, Dual Combination Doravirine/Raltegravir Open Label DORAVIRINE 100 MG [Pifeltro] - HIV Infections | Phase 2 | Recruiting | Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida | 150 | 2020-09-15 | 2025-01-10 |
| Neuropsyquiatric Evolution After Introduction of Raltegravir QD in Substitution of Dolutegravir: NEAR QD Study Raltegravir - HIV Infections | Phase 4 | Unknown | Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud | 50 | 2019-05-01 | 2019-02-15 |
| Raltegravir One Thousand Two Hundred vs Darunavir-cb in Immnunosupressed Patients: ROTDIP Study Experimental: RAL QD, Active comparator: DRV/cb - HIV Infections | Phase 4 | Unknown | Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud | 75 | 2019-04-01 | 2019-02-15 |
| Safety, Tolerability, and Pharmacokinetics of Raltegravir (MK-0518) in Healthy Japanese Male Participants (MK-0518-851) Raltegravir - Human Immunodeficiency Virus (HIV) Infection | Phase 4 | Completed | Merck Sharp & Dohme LLC | 12 | 2018-09-27 | 2019-10-02 |
| RESIST-2: 2nd-line ART for HIV-2 Infection HIV-2 Genotypic Drug Resistance Testing using DBS, 2nd line ART ( Zidovudine 300mg BID + Lamivudine 150mg BID or Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID), 2nd line ART (Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID + Raltegravir 400mg BID ) - HIV-2 Infection | Not applicable | Terminated | University of Washington | 152 | 2018-07-04 | 2021-01-25 |
| Study With Dual Therapy Including Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) in Virologically Suppressed HIV-1 Infected Patients Experiencing Inconvenience, Toxicity, Negative Impact on Co-morbidities or Risk of Drug-drug Interactions With Their Current Regimen Raltegravir, Lamivudine - HIV Seropositivity, HIV Infections | Phase 3 | Terminated | Judit Pich | 17 | 2018-05-03 | 2025-05-18 |
| Simplification Study of HIV-1 Infected Patients With Virological Suppression Under the Combination of Lamivudine (150 mg BID) Plus Raltegravir (400 mg BID) Switching to Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) : Roll-over Study of the RALAM Raltegravir, Lamivudine - HIV Infections, HIV-1-infection | Phase 3 | Completed | Judit Pich | 33 | 2018-05-02 | 2025-07-18 |
| Effect on Liver Fat and Metabolic Parameters When Switching a Protease Inhibitor or Efavirenz to Raltegravir Raltegravir - HIV Seropositivity, Metabolic Syndrome | Phase 4 | Completed | Helsinki University Central Hospital | 45 | 2018-01-10 | 2021-09-05 |
| QDISS Stud: QD Isentress as Switch Strategy in Virologically Suppressed HIV-1 Infected-Patient Raltegravir and 2 Nucleoside/Nucleotide reverse transcriptase inhibitor (NRTI) - Virus-HIV | Phase 2 | Completed | Nantes University Hospital | 100 | 2017-11-08 | 2026-09-14 |
| Time to Protection and Adherence Requirements of Raltegravir With or Without Lamivudine in Protection From HIV Infection Raltegravir 400Mg Tab, Lamivudine 150Mg Tablet - Hiv | Phase 4 | Completed | Guy's and St Thomas' NHS Foundation Trust | 38 | 2017-09-19 | 2021-03-16 |
| Clinical Trial to Evaluate the Effect of Raltegravir Intensification (1.200 mg QD) on the Gut Microbiota of Chronically HIV-1 Infected Subject Over Time: THE RAGTIME STUDY Raltegravir, Placebo, Current ART - HIV | Phase 3 | Completed | Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia | 61 | 2017-07-28 | 2025-06-17 |
| Effect of Raltegravir in Patients With Acute Tropical Spastic Paraparesis - Human T-Lymphotropic Virus 1 Infection "Raltegravir" and "Zidovudine" - HTLV-I Infections, Tropical Spastic Paraparesis | Early Phase 1 | Completed | Universidad Peruana Cayetano Heredia | 10 | 2017-07-01 | 2019-05-22 |
| Population Pharmacokinetics of Antiretroviral in Children Dolutegravir, Raltegravir, Rilpivirine - Minor Patient Treated by One or More Antiretroviral and for Which a Blood Test Has Been Performed | Completed | Assistance Publique - Hôpitaux de Paris | 65 | 2017-06-16 | 2026-04-03 | |
| A Drug Interaction Study to Assess the Pharmacokinetics of Narlaprevir and Antiretroviral Drugs Narlaprevir, Ritonavir, Tenofovir Disoproxil Fumarate - Healthy | Phase 1 | Completed | R-Pharm | 36 | 2017-04-24 | 2019-02-19 |
| First-Line Treatment for HIV-2 Tenofovir + Emtricitabine or Lamivudine + Zidovudine, Tenofovir + Emtricitabine or Lamivudine + Lopinavir/ritonavir, Tenofovir + Emtricitabine or Lamivudine + Raltegravir - HIV-2 Infection | Phase 2 / Phase 3 | Completed | ANRS, Emerging Infectious Diseases | 210 | 2016-01-26 | 2019-07-22 |
| Research In Viral Eradication of HIV Reservoirs Combination Antiretroviral Therapy (cART), Raltegravir, Vorinostat - HIV | Phase 2 | Completed | Imperial College London | 60 | 2015-11-27 | 2023-10-23 |
Showing 20 of 229. Sign in to see all of them.
HIV Infections (128) · Acquired Immunodeficiency Syndrome (39) · Hepatitis C (8) · Infections (7) · Tuberculosis (6) · HIV Seropositivity (5) · Coinfection (3) · Depression (3) · Bone Diseases, Metabolic (2) · Cardiovascular Diseases (2) · Cognitive Dysfunction (2) · Fatty Liver (2) · HTLV-I Infections (2) · Hepatitis C, Chronic (2) · Hyperlipidemias (2)
Merck Sharp & Dohme LLC (18) · ANRS, Emerging Infectious Diseases (12) · National Institute of Allergy and Infectious Diseases (NIAID) (9) · Radboud University Medical Center (7) · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (6) · St Stephens Aids Trust (6) · Kirby Institute (5) · University of California, San Francisco (5) · ViiV Healthcare (5) · Germans Trias i Pujol Hospital (4) · Hospital Clinic of Barcelona (4) · University of North Carolina, Chapel Hill (4) · Boehringer Ingelheim (3) · Bristol-Myers Squibb (3) · Community Research Initiative of New England (3)
United States (89) · Spain (29) · France (24) · United Kingdom (19) · Brazil (15) · South Africa (14) · Argentina (13) · Canada (12) · Australia (10) · Puerto Rico (10) · Thailand (10) · Germany (9) · Italy (9) · Netherlands (9) · Kenya (6)
Angela DM Kashuba, PharmD (3) · Christine Katlama, MD (3) · Marta Boffito (3) · Alan Winston, MB BH (2) · Andrew D Carr, Professor (2) · Beatriz Grinsztejn, MD, PhD (2) · David V Condoluci, DO (2) · Diana F. Clarke, PharmD (2) · Kristine B Patterson, MD (2) · Marta Boffito, Dr (2)
PMID 20085491, PMID 21436711, PMID 24204757, PMID 25904376, PMID 26797215, PMID 35179037, PMID 12522449, PMID 15472843, PMID 16470119, PMID 16988514, PMID 17376384, PMID 18366444, PMID 18795962, PMID 18989231, PMID 19213682, PMID 19578703, PMID 19590405, PMID 19647866, PMID 19717722, PMID 19819183, PMID 19834480, PMID 20002783, PMID 20074791, PMID 20156060, PMID 20186346, PMID 20395869, PMID 20404738, PMID 20467288, PMID 20573027, PMID 20632458, PMID 20711481, PMID 20827162, PMID 20921313, PMID 20939732, PMID 20974575, PMID 21198432, PMID 21283017, PMID 21343468, PMID 21368592, PMID 21402547, PMID 21406434, PMID 21434946, PMID 21522004, PMID 21599819, PMID 21857490, PMID 21860347, PMID 21921224, PMID 21930607, PMID 21933752, PMID 21965433
2009 (7), U01AI068636 (6), 2014 (3), 2008 (2), 2017 (2), UM1AI068616 (2), 5UM1AI068634 (1), K23AI077355 (1), P30AI050410 (1), R01AI064074 (1), R01AI120765 (1), R01DA013806 (1), R01DA025932 (1), R01MH058076 (1), R01MH062701 (1)